[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,797
  • Shares Outstanding, K 234,696
  • Annual Sales, $ 48,470 K
  • Annual Income, $ -170,370 K
  • EBIT $ -171 M
  • EBITDA $ -176 M
  • 60-Month Beta 2.15
  • Price/Sales 1.60
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings $-0.21 on 03/17/26
  • Next Earnings Date 05/21/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 460.55% (+309.54%)
  • Historical Volatility 177.44%
  • IV Percentile 95%
  • IV Rank 69.58%
  • IV High 633.32% on 02/20/26
  • IV Low 65.36% on 08/20/25
  • Expected Move (DTE 31) 0.2550 (132.33%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 3,373
  • Volume Avg (30-Day) 417
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 54,097
  • Open Int (30-Day) 74,050
  • Expected Range 0.0000 to 0.4477

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 4
  • High Estimate $-0.05
  • Low Estimate $-0.23
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1626 +18.51%
on 05/18/26
0.4600 -58.11%
on 04/20/26
-0.2533 (-56.79%)
since 04/17/26
3-Month
0.1626 +18.51%
on 05/18/26
2.2263 -91.34%
on 02/19/26
-1.9773 (-91.12%)
since 02/18/26
52-Week
0.1626 +18.51%
on 05/18/26
3.8700 -95.02%
on 12/15/25
-0.8473 (-81.47%)
since 05/16/25

Most Recent Stories

More News
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their...

GOSS : 0.1927 (-43.32%)
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

SAN FRANCISCO , May 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. ( NASDAQ: GOSS ) and an executive, seeking to represent investors who...

GOSS : 0.1927 (-43.32%)
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)...

GOSS : 0.1927 (-43.32%)
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including...

GOSS : 0.1927 (-43.32%)
Gossamer Bio: Q1 Earnings Snapshot

Gossamer Bio: Q1 Earnings Snapshot

GOSS : 0.1927 (-43.32%)
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.1927 (-43.32%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors...

GOSS : 0.1927 (-43.32%)
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 14, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

GOSS : 0.1927 (-43.32%)
GOSS Investor Alert: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

SAN FRANCISCO , May 14, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. ( NASDAQ: GOSS ) and an executive, seeking to represent investors who...

GOSS : 0.1927 (-43.32%)
GOSS INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options

GOSS : 0.1927 (-43.32%)

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 0.4117
2nd Resistance Point 0.3558
1st Resistance Point 0.2743
Last Price 0.1927
1st Support Level 0.1369
2nd Support Level 0.0810
3rd Support Level N/A

See More

52-Week High 3.8700
Fibonacci 61.8% 2.4538
Fibonacci 50% 2.0163
Fibonacci 38.2% 1.5788
Last Price 0.1927
52-Week Low 0.1626

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.